@article{5e5434f4-3341-4a15-bcff-aa07548fbd2e,
  author       = {{Matino, Davide and Frenzel, Laurent and Bulent Antmen, Ali and Astermark, Jan and Cerqueira, Monica H. and Cuker, Adam and Katsarou-Fasouli, Olga and Kavakli, Kaan and Ozelo, Margareth C. and P'ng, Stephanie and Wang, Jiaan Der and Agathon, Delphine and Biondo, Francesca and Klaus, Pascal and McKay, John and Rupon, Jeremy and Sun, Pengling and Wilcox, Lisa J. and Plonski, Frank}},
  issn         = {{1351-8216}},
  keywords     = {{annualised bleeding rate (ABR); fidanacogene elaparvovec; gene therapy; haemophilia B; haemophilia joint health score (HJHS); joint health}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{1}},
  pages        = {{334--339}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Haemophilia}},
  title        = {{Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B : Results From a Phase 3 Study}},
  url          = {{http://dx.doi.org/10.1111/hae.70150}},
  doi          = {{10.1111/hae.70150}},
  volume       = {{32}},
  year         = {{2026}},
}